Using Evidence-Based Medicine to Guide the Prevention and Therapy of Cardiovascular Diseases_Chinese Journal of Evidence-Based Medicine

Authors：

胡大一

Corresponding author：

Keywords：

Evidence-based medicine; Prevention of cardiovascular disease; Medical education; Randomized controlled trial; Clinical guideline

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 胡大一. Using Evidence-Based Medicine to Guide the Prevention and Therapy of Cardiovascular Diseases. Chinese Journal of Evidence-Based Medicine, 2004, 04(5): 285-287. doi: Copy

1.	［1］The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction[J]. N Engl J Med, 1989; 321:406-412.
2.	［2］Furberg CD, Bruce M, Jeffrey V. Nifedipine Dose-Related Increase in Mortality in Patients With Coronary Heart Disease[J].Circulation, 1995; 92:1 326-1 331.
3.	［3］The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial ( ALLHATLLT) [J]. JAMA, 2002; 288:2 998-3 007.
4.	［4］Sever PS, DahlofB, Poulter NB, Wedel H, Beevers G,Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised trial [ J ]. Lancet,2003; 361:1149-1158.

1. ［1］The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction[J]. N Engl J Med, 1989; 321:406-412.
2. ［2］Furberg CD, Bruce M, Jeffrey V. Nifedipine Dose-Related Increase in Mortality in Patients With Coronary Heart Disease[J].Circulation, 1995; 92:1 326-1 331.
3. ［3］The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial ( ALLHATLLT) [J]. JAMA, 2002; 288:2 998-3 007.
4. ［4］Sever PS, DahlofB, Poulter NB, Wedel H, Beevers G,Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised trial [ J ]. Lancet,2003; 361:1149-1158.

Chinese Journal of Evidence-Based Medicine

Using Evidence-Based Medicine to Guide the Prevention and Therapy of Cardiovascular Diseases

Abstract Full text Figures/Tables Video References Cited by

Format

Content